Trial Profile
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results assessing efficacy of mitoxantrone, etoposide, and Cytarabine (MEC),and Lenalidomide (Len) combination,presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Jan 2021 Planned End Date changed from 30 Sep 2024 to 1 Aug 2021.
- 13 Jan 2021 Status changed from recruiting to active, no longer recruiting.